The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant melanoma: inhibiting the gene S6K2. .

Turnstone, which went public via an $80 million IPO in 2023, ended September 2024 with $45.3 million to hand, which the ...

We present a case of unilateral, secondary open-angle glaucoma due to an underlying diffuse iris melanoma. The patient was referred by his ophthalmologist with uncontrolled, elevated intraocular ...

Mayo Clinic's organoids, microscopic versions of organs that function like the real ones, have been used by doctors to study ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in ...

ROCHESTER, Minnesota — Mayo Clinic researchers have developed  organoid models  to study  uveal melanoma , one of the most common types of eye cancer ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these models to better understand how this ...

Sep. 16, 2024 — Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune ... Experimental mRNA Cancer Vaccine ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on CSTL stock, giving a Buy rating yesterday.Invest with Confidence: ...

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Immunocore Holdings (IMCR – Research Report), retaining the price target ...